Original articleRisk of new-onset inflammatory bowel disease among patients with acne vulgaris exposed to isotretinoin
Section snippets
Patient population
This was a retrospective cohort study using a multi–health system data analytics and research platform (Explorys) developed by IBM Corporation, Watson Health.10 Clinical information from electronic medical records, laboratories, practice management systems, and claims systems was matched using the single set of Unified Medical Language System ontologies to create longitudinal records for unique patients. Data are standardized and curated according to common controlled vocabularies and
Results
We identified 27,230 patients with AV with isotretinoin exposure and 631,089 control patients whose demographic characteristics are described in Table I. Patients with AV in the isotretinoin cohort were predominantly aged 15 to 29 years (72%), were white (87%), and had similar distributions of male and female patients.
Among patients with AV with isotretinoin exposure, the crude 6-month incidence of IBD was 0.08% (21/27,230) compared to 0.04% (254/631,089) among patients with AV without exposure
Discussion
In this analysis, we observed very low incidence of IBD among patients with AV exposed to isotretinoin at 6 months and at 1 year after the first exposure. Although the 6-month incidence of IBD was slightly higher among those exposed to isotretinoin, this difference was small, with 2.6 more cases of IBD per 10,000 persons in the isotretinoin group. Based on the estimated risk difference, for every 3846 patients treated with isotretinoin, 1 more case of IBD would be observed within 6 months than
References (19)
- et al.
Isotretinoin use and the risk of inflammatory bowel disease: a population-based cohort study
J Invest Dermatol
(2013) - et al.
Identifying Chinese herbal medicine network for treating acne: implications from a nationwide database
J Ethnopharmacol
(2016) - et al.
Isotretinoin and ulcerative colitis: a case report and review of the literature
World J Gastrointest Surg
(2014) - et al.
Isotretinoin-induced inflammatory bowel disease in an adolescent
Ann Pharmacother
(2001) - et al.
Isotretinoin-associated pan-enteritis
J Clin Gastroenterol
(2008) - et al.
Isotretinoin use and the risk of inflammatory bowel disease: a case-control study
Am J Gastroenterol
(2010) - et al.
Isotretinoin and risk of inflammatory bowel disease: a French nationwide study
Am J Gastroenterol
(2014) - et al.
Isotretinoin and risk for inflammatory bowel disease a nested case-control study and meta-analysis of published and unpublished data
JAMA Dermatol
(2013) - et al.
Isotretinoin is not associated with inflammatory bowel disease: a population based case-control study
Am J Gastroenterol
(2009)
Cited by (0)
Funding sources: None.
Disclosure: Dr Garg is an advisor for AbbVie, Amgen, Boehringer Ingelheim, Incyte, Janssen, Novartis, Pfizer, UCB, and Viela Bio and receives research grants from AbbVie and National Psoriasis Foundation. Authors Wright and Strunk have no conflicts of interest to declare.
IRB approval status: Reviewed and approved by the human subjects committee at the Feinstein Institutes for Medical Research at the Northwell Health.
Reprints not available from the authors.